Kymera Therapeutics (KYMR) Corporate presentation summary

Strategic vision and innovation

• Focus on revolutionizing immunology with oral medicines that match biologics in efficacy and safety.

• Developed targeted protein degradation (TPD) as a reproducible innovation engine, unlocking previously undrugged targets.

• Advanced six first-in-class molecules into clinical trials, validating mechanisms from preclinical to patient studies.

• Aims to commercialize oral medicines to improve access and outcomes, expanding into new therapeutic areas.

• Unique chemistry and drug development strategies enable targeting of highly validated, historically undrugged pathways.

Market opportunity and unmet needs

• Over 160 million patients diagnosed with immunological diseases in major markets, but only 3% access advanced therapies.

• Advanced systemic therapies are mostly injectable biologics, which are inconvenient, costly, and have immunogenicity risks.

• More than 90% of patients would prefer an oral option over injectables.

• Existing therapies address 10% or less of diagnosed patients in key indications like AD, asthma, COPD, SLE, and RA.

Pipeline highlights and clinical progress

• KT-621 is a first-in-class, highly selective oral STAT6 degrader showing dupilumab-like efficacy in preclinical and clinical studies.

• Phase 1b data in atopic dermatitis (AD) showed deep STAT6 degradation, robust biomarker reductions, and meaningful clinical improvements.

• Phase 2b trials ongoing in AD (BROADEN2, data mid-2027) and asthma (BREADTH, data late 2027).

• KT-579, an oral IRF5 degrader, demonstrated robust cytokine inhibition and efficacy in lupus and RA models, with Phase 1 data expected in 2H 2026.

• Partnered programs include KT-485 (oral IRAK4 degrader, Phase 1 with Sanofi) and KT-200 (oral CDK2 degrader, IND-enabling with Gilead).